Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 5/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MPL | P40238 | 5/20 | 0.38 |
| ▸ | RARB | P10826 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | CHKA | P35790 | 1/20 | 0.35 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16572151 | 0.91 | CA1 (0.51) | LPLLIPGCA1CA2MPL | |
| SCHEMBL7764726 | 0.89 | LPL (0.53) | LPLLIPGCA1CA2MPL | |
| SCHEMBL29950872 | 0.89 | LPL (0.53) | LPLLIPGCA1CA2MPL | |
| SCHEMBL7789321 | 0.88 | LIPG (0.54) | LPLLIPGCA1CA2RARB | |
| SCHEMBL7786816 | 0.88 | LIPG (0.54) | LPLLIPGCA1CA2RARB | |
| SCHEMBL18160348 | 0.88 | LPL (0.46) | LPLLIPGCA1CA2MPL | |
| SCHEMBL3031530 | 0.87 | LPL (0.46) | LPLLIPGMPLRARBCHKA | |
| SCHEMBL9494063 | 0.86 | LPL (0.42) | LPLLIPGCA2MPLRARB | |
| SCHEMBL29281551 | 0.86 | LIPG (0.47) | LPLLIPGCA1CA2MPL | |
| SCHEMBL9563689 | 0.84 | MCL1 (0.41) | LPLLIPGCA2MPLRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023799-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-07-17 | — | — | US | disclosed |
| US-20150376504-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20150376504-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-12-31 | — | — | US | disclosed |
| EP-1388538-B1 | Polymerisation Initiator | MERCK PATENT GMBH (DE) | 2010-09-01 | — | — | EP | disclosed |
| EP-1388538-A1 | Polymerisation Initiator | MERCK PATENT GmbH (DE) | 2004-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023799-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | PIEZO1, ROCK1, RCC1 | LPL 1032/4885LIPG 1678/4885CA1 377/4885 |
| US-20150376504-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | PIEZO1, ROCK1, RCC1 | LPL 1032/4885LIPG 1678/4885CA1 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.